SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending following news of its acquisition of Metsera, a weight-loss drug developer, for a potential $7.3 billion. While some see this as a strategic move to enter the growing obesity market, others question the timing and price, noting the competitive landscape. The community is actively discussing the implications for Pfizer's pipeline, potential competition with other GLP-1 drugs, and whether this will finally boost the undervalued stock.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending downwards, with community members discussing the impact of prediction markets and increased competition from platforms like Kalshi and Robinhood. Some traders are speculating about potential support levels and whether the company will adapt its strategy. Despite the bearish sentiment, some investors see the dip as a buying opportunity, citing the company's strong position in the sports betting sector.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy Corp

Bloom Energy ($BE) is trending due to growing optimism surrounding its role in powering AI data centers, with the community discussing the potential for significant growth and high price targets. A recent application for fuel cells to power a large power plant in Wyoming, along with comments from the Energy Secretary about hydrogen's role in powering the grid, are driving bullish sentiment. Community members are noting the stock's momentum and discussing potential short squeezes given the high short interest.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as the community rallies around its vision of linking crypto with cannabis culture, emphasizing freedom and growth within the digital space. Discussions highlight its potential as a culture coin, with community members sharing positive sentiments and links to purchase on Pump.fun and Dexscreener. The coin is also drawing attention for its association with the broader cannabis sector.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending following the announcement of partnerships with OpenAI, Snowflake, and Nvidia to enhance its automation platform with advanced AI. Community members are actively discussing the potential impact of these partnerships on UiPath's market position and revenue growth, as well as comparing it to other AI stocks like Palantir. Despite positive news, some traders remain cautious, citing concerns about the CEO's stock sales and broader market conditions.

Draganfly, Inc. engages in the manufacture and sale of commercial unmanned aerial vehicle systems and software serving the public safety, agriculture, industrial inspections, security, mapping, and surveying markets. Its products include quad-copters, fixed wing aircrafts, ground based robots, hand held controllers, and software used for tracking, live streaming, and data collection. The firm also offers custom engineering, training, simulation consulting, as well as data and flight training services. The company was founded by Zenon Dragan and Christine Dragan in 1998 and is headquartered in Saskatoon, Canada.

Draganfly Inc

DPRO is trending due to news of the company being selected by the U.S. Army to supply drone systems, including manufacturing and training support at overseas facilities, though financial terms were not disclosed. The community is discussing the potential impact of this military contract, with some speculating about a possible short squeeze given the stock's high short interest. Bullish sentiment is fueled by the company's position in the growing drone warfare market, while others express concerns about potential offerings.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending amid discussions about upcoming earnings and a potential turnaround, with community members debating whether the stock can break out. Recent partnerships, such as the SKIMS collaboration, are generating buzz, while analysts weigh in on the impact of tariffs and competition. Some traders are also closely monitoring technical indicators and potential trading strategies around the stock.

This is a legacy token commemorating the pseudonym Satoshi Nakamoto.

Satoshi Nakamoto

$SATOSHI.X is trending as the community emphasizes its significance as the tokenization of Satoshi Nakamoto, the pseudonymous creator of Bitcoin. Many believe it represents the ethos of the entire crypto industry, calling it a 'second chance at Bitcoin' and highlighting the 'We Are All Satoshi' movement. Discussions also revolve around its potential for growth and NFT integration.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is trending as the stock experiences high volatility amid discussions around government contracts and future revenue potential. Community members are debating the merits of the company's long-term prospects versus its current valuation, with some pointing to insider selling and potential risks. Others highlight the significance of nuclear energy for AI and data centers, anticipating further gains despite recent price swings.

HCM II Acquisition Corp. operates as a blank check company. It was formed for the purpose of entering into a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on April 4, 2024 and is headquartered in Stamford, CT.

HCM II Acquisition Corp - Ordinary Shares - Class A

HCM II Acquisition Corp.

HCM II Acquisition Corp. ($HOND) is trending due to its upcoming merger with Terrestrial Energy and recent selection by the Department of Energy for its new reactor pilot program, generating excitement around its molten salt reactor technology. The community is comparing $HOND to other nuclear energy companies like $OKLO and speculating on its potential valuation post-merger, with some anticipating significant upside. Some users point to ZipTrader Charlie's coverage as a catalyst for increased interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Incannex Healthcare Inc. (IXHL) has experienced a 234% increase in retail chatter on Stocktwits over the past seven days, while message volumes have risen 193% over the past 30 days on the platform. Shares of the company drew investor attention on Wednesday morning as it declined nearly 10% at the opening bell.Incannex is developing combination medicines for several chronic conditions, including obstructive sleep apnoea, rheumatoid arthritis, and generalised anxiety disorder. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IXHL">IXHL stock</a> jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:574/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_24_at_9_16_43_AM_png_8958508111.webp" alt="IXHL's Sentiment Meter and Message Volume as of 9:17 a.m. ET on Sept. 24, 2025 | Source: Stocktwits" width="574" height="66"><figcaption>IXHL's Sentiment Meter and Message Volume as of 9:17 a.m. ET on Sept. 24, 2025 | Source: Stocktwits</figcaption></figure>Last month, the company <a href="https://stocktwits.com/news-articles/markets/equity/why-is-incannex-healthcare-surging-today/chsHHZBRdjh">announced </a>positive data from a mid-stage trial evaluating PSX-001 for Generalised Anxiety Disorder (GAD). The company stated that the trial results confirm statistically significant and clinically meaningful improvements across all key endpoints assessed, including the Hamilton Anxiety Rating Scale. The trial enrolled 73 adult participants diagnosed with moderate to severe Generalised Anxiety Disorder.PSX-001, also called Psi-GAD, is a psilocybin-assisted psychotherapy treatment. Patients treated with PSX-001 in the study achieved an average 12.8-point reduction in Hamilton Anxiety Rating Scale scores from baseline, compared to a 3.6-point decrease in the placebo group.Of patients receiving treatment, 27% achieved complete disease remission, which is five times higher than the placebo rate, the company said. Additionally, the firm is exploring strategic partnerships to accelerate development and broaden global access to PSX-001.The company’s other two clinical-stage product candidates, IHL-42X and IHL-675A, are in different stages of development. While IHL-42X has completed a mid-stage clinical trial in obstructive sleep apnoea, IHL-675A is currently in a mid-stage clinical development program for the treatment of inflammatory conditions such as Arthritis.Incannex also <a href="https://stocktwits.com/news-articles/markets/equity/incannex-stock-soars-after-board-authorizes-20-million-share-repurchase-program/chsZIp3RdK2">authorized</a> a $20 million share repurchase program in August. CEO Joel Latham had stated that the program reflects the company’s confidence in the strength of its pipelines and the opportunities ahead. “We believe the current market valuation does not accurately reflect the significant progress we have made across our clinical programs,” he said.A Stocktwits user, meanwhile, expressed hopes for a partnership or buyout announcement on the company’s next earnings announcement.<stembedurl>https://stocktwits.com/IKEGAI/message/629801176</stembedurl>Shares of the company slumped 71% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/acadia-health-care-stock-surges-pre-market-after-activist-hedge-fund-reportedly-seeks-board-revamp/chD1bdjR33W">Acadia Healthcare Stock Surges After Activist Hedge Fund Reportedly Seeks Board Revamp</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Incannex Healthcare Inc. logo is seen on a smartphone and in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Incannex Healthcare Stock Sees Retail Chatter Explode 234% Over Last Week

The company is developing combination medicines for several chronic conditions, including obstructive sleep apnoea, rheumatoid arthritis, and generalised anxiety disorder.

Equity

The company is developing combination medicines for several chronic conditions, including obstructive sleep apnoea, rheumatoid arthritis, and generalised anxiety disorder.


Incannex Healthcare Inc. (IXHL) on Tuesday announced positive data from a mid-stage trial evaluating PSX-001 for Generalised Anxiety Disorder (GAD). The stock shot up nearly 15% in Tuesday’s pre-market session.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.incannex.com/news-releases/news-release-details/incannex-reports-positive-results-phase-2-clinical-trial-psx-001">said</a> that the results from the trial confirm statistically significant and clinically meaningful improvements across every key endpoint assessed in the study, including on the Hamilton Anxiety Rating Scale. The trial enrolled 73 adult participants diagnosed with moderate to severe Generalised Anxiety Disorder.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IXHL">IXHL stock</a> jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.PSX-001, also called Psi-GAD, is a psilocybin-assisted psychotherapy treatment. Patients treated with PSX-001 in the study achieved an average 12.8-point reduction in Hamilton Anxiety Rating Scale scores from baseline, compared to a 3.6-point decrease in the placebo group. This difference was statistically significant and sustained across the 11-week follow-up period, the company said.Of patients receiving treatment, 27% achieved full disease remission, five times higher than placebo. Quality of life also improved by an average of 10.6 points on the Personal Wellbeing Index in the PSX-001 group versus 2.7 points for placebo. “Psi-GAD demonstrated a reduction in anxiety, improved mood, enhanced quality of life, and better day-to-day functioning. Importantly, the treatment effect was durable and observed across 11 weeks,” said Lou Barbato, Chief Medical Officer of Incannex.The company is now preparing to initiate a multi-jurisdiction mid-stage clinical trial. Incannex is also exploring strategic partnerships to accelerate development and broaden global access to PSX-001.Treatment with Psi-GAD was well tolerated across the study population, the company said. The majority of treatment-emergent adverse events (TEAEs) were transient, mild to moderate in nature, and consistent with the expected pharmacological effects of Psilocybin, the company said. It added that there were no signs of concerns often cited with psychedelic treatments, such as increased suicidality, psychosis, or prolonged psychological distress. However, one subject withdrew from the trial, Incannex said.&nbsp;IXHL stock is down by 65% this year and by 61% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-oral-drug-delivers-significant-weight-loss-in-late-stage-study/chsHtgtRdj7">Eli Lilly’s Oral Drug Delivers Significant Weight Loss In Late-Stage Study</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Why Is Incannex Healthcare Stock Surging Today? 

The company said that the results from its mid-stage trial evaluating PSX-001 for Generalised Anxiety Disorder confirm statistically significant and clinically meaningful improvements across every key endpoint assessed in the study.

Incannex Healthcare Inc. (IXHL) announced on Friday that its board of directors has authorized a share repurchase program for up to $20 million of the company’s outstanding shares of common stockShares of the company were up 23% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IXHL">IXHL stock</a> improved from ‘extremely bearish’ to ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘extremely low’ levels.<figure class="image"><img style="aspect-ratio:573/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_22_at_11_04_37_AM_png_83c7c67ea2.webp" alt="IXHL's Sentiment Meter and Message Volume as of 11 a.m. ET on Aug. 22, 2025 | Source: Stocktwits" width="573" height="60"><figcaption>IXHL's Sentiment Meter and Message Volume as of 11 a.m. ET on Aug. 22, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed hopes that the stock will trade over $1 soon.<stembedurl>https://stocktwits.com/Uppy/message/626218079</stembedurl>The company said that it may repurchase shares of common stock through open market purchases, privately negotiated transactions, accelerated share repurchase arrangements, or other methods. The timing and amount of any repurchases will depend on market conditions, available capital resources, among other factors, it <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.incannex.com/news-releases/news-release-details/incannex-healthcare-authorizes-20-million-share-repurchase">added</a>.CEO Joel Latham said that the firm believes the current market valuation does not accurately reflect the significant progress it has made across its clinical programs. “This initiative allows us to act decisively, strengthen our capital management strategy, and potentially enhance long-term value creation for shareholders,” he added.Incannex has three clinical-stage product candidates. Its lead candidate, IHL-42X, an oral fixed-dose combination of Dronabinol and Acetazolamide, is designed for the treatment of obstructive sleep apnea. The other programs are in development for rheumatoid arthritis and generalized anxiety disorder.In July, the company said that it is well-positioned to advance its portfolio of drug candidates through the next stages of development with a cash balance of about $50 million.IXHL stock is down by 73% this year and by 68% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/macquarie-downgrades-li-auto-on-rising-competition-in-chinese-market/chsZ3xRRdKb">This Stock Just Got Downgraded By Macquarie On Rising Competition In Chinese Market – Do You Own It?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

This Pharma Stock Soared 23% Today But Is Still Down Over 70% In 2025 – Find Out More

The company’s CEO said that the current market valuation does not accurately reflect the significant progress the firm has made across its clinical programs.

Shares of Incannex Healthcare Inc. hit their highest levels in nearly two months on Wednesday after the company released updates about its lead candidate, IHL-42X, a once-daily oral treatment for obstructive sleep apnea (OSA).The company announced completion of patient dosing for the Phase 2 portion of the RePOSA Phase 2/3 trial on May 8 and expects to finish final follow-up assessments by May 17.&nbsp;Shares of Incannex surged 720% on May 14 to close at $0.70, with the stock rising another 24% to $0.87 in after-hours trading.The program's pharmacokinetic and safety profiles, and clinical knowledge will help progress upcoming development stages and regulatory discussions with the FDA.The FDA end-of-Phase II meeting will formulate regulatory approaches for a new drug application.The company started its Phase 3 preparations, which will enroll 440 patients across multiple U.S. trial sites. U.S. investigators and trial participants drove the decision to concentrate geographically.IHL-42X treats intermittent hypoxia, defined by repeated blood oxygen level decreases, and hypercapnia, which involves carbon dioxide accumulation in the blood from inadequate airflow during sleep.Patients receive a dual therapy of dronabinol and acetazolamide to achieve combined effects that lessen disease severity.The Australian Phase 2 trials revealed that the lowest dose achieved a 51% reduction in the Apnea-Hypopnea Index (AHI) on average.&nbsp;Subsequent studies reported progress in measuring hypoxic burden (HB), which shows a stronger link to cardiovascular outcomes compared to AHI measurements.The company pointed out that IHL-42X may be used as a broader treatment option than weight loss therapies because data reveals that 67% of OSA patients are not obese.&nbsp;It also announced initiation of early commercial engagement initiatives, which demonstrate increasing attention from prospective partners.&nbsp;Incannex has advanced multiple late-stage drug candidates, including IHL-675A targeting inflammatory conditions and PSX-001 for generalized anxiety disorder.&nbsp;On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume.One user suggested the sharp move in Incannex was part of what they described as a broader wave of "penny bio pharma mania" unfolding in the market.<stembedurl>https://stocktwits.com/StockFlips/message/614689194</stembedurl>Meanwhile, another user expressed regret over missing the rally while driving and hoped the stock would climb again the next day.<stembedurl>https://stocktwits.com/Moodymoney/message/614690960</stembedurl>The stock has declined 65.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Incannex Surges 720% On Sleep Apnea Trial Progress: ‘Penny Bio Pharma Mania’ Lifts Retail Sentiment

The company completed patient dosing in its Phase 2/3 trial for IHL-42X, a once-daily oral treatment for obstructive sleep apnea. Retail enthusiasm surged as the company eyes FDA talks, Phase 3 rollout in the U.S., and early commercial interest.

Incannex Secures $60M Financing To Drive Advances In Psychedelic And Cannabinoid Therapies

Incannex Healthcare secures $60M in financing from Arena Investors to support clinical trials for cannabinoid and psychedelic therapies.
read more...

FDA Experts Weigh In On Incannex's CannQuit-O With Feedback On CBD As Treatment For Opioid Use Disorder

Incannex Healthcare Inc., a cannabinoid and psychedelic medicine biotechnology company, announced the successful completion of a pre-investigational new drug meeting with the U.S. Food and Drug...

Incannex Healthcare Inc. (NASDAQ:IXHL) Short Interest Up 113.1% in March

Incannex Healthcare Inc. (NASDAQ:IXHL - Get Free Report) was the recipient of a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 208,200...

Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder

Appendix: Comparison of PsiGAD Treatments to Existing Registered Treatments for Anxiety

 Figure: meta-analysis(1) of psychotropic medications for GAD, as measured by the HAM-A; the best...

Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation

MELBOURNE, Australia and NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex or the Company), a leading cannabinoid and psychedelic medicine biotechnology...

Is Incannex Healthcare (NASDAQ:IXHL) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Incannex Healthcare, Inc. is a biotech company, which engages in developing cannabinoid and psychedelic compound medicines. It focuses on the research and development for medicinal cannabis pharmaceutical products and psychedelic medicine therapies for treatment of a range of indications. The company was founded on July 5, 2023 and is headquartered in Norwest, Australia.

Incannex Healthcare Inc

0 to 25,000

25,000 to 50,000

50,000 to 75,000

75,000 to 100,000

How many jobs did the U.S. add in September? Vote below + drop your exact prediction in the comments. 
 
*Powered by Polymarket

Current Price	$0.4739
Prev Close	$0.519
Open	$0.5046
Dividend Yield	0.00%
50-Day Moving Average	$0.6104
Beta	0.00
Avg. Volume	144.09M
PE Ratio	-0.41

52-Week High	$3.12
52-Week Low	$0.08
Market Capitalization	$48.63M
EPS (Annual)	-$1.36
Price to Book	1.25
Revenue Per Employee	$7,166.67
Enterprise Value/EBITDA	N/A

IXHL
Incannex Healthcare Limited - ADR

Feed

News

Sentiment

Fundamentals

Info

Latest IXHL News

IXHL Incannex Healthcare Limited - ADR